Bet Inhibitor Gsk525762
Bet Inhibitor Gsk525762 Uses, Dosage, Side Effects, Food Interaction and all others data.
Bet Inhibitor Gsk525762 is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies).
| Trade Name | Bet Inhibitor Gsk525762 |
| Generic | Molibresib |
| Molibresib Other Names | Bet inhibitor gsk525762, Molibresib |
| Type | |
| Formula | C22H22ClN5O2 |
| Weight | Average: 423.9 Monoisotopic: 423.1462027 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Bet Inhibitor Gsk525762
